Handelsavisen
prelaunch
Companies ›Healthcare ›XERS.O
XE
XERS.O — NASDAQ Pharmaceuticals

Xers.O

$8,13
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
8,5 %
ROE
4,0 %
Net margin
0,2 %
Debt / equity
16,10
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$8,42
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Xeris Biopharma Holdings Inc operates as a pharmaceutical company with subsidiaries including Xeris Pharmaceuticals, Inc and Strongbridge Biopharma Limited, generating revenue through the development and manufacturing of products such as Recorlev and levoketoconazole.

Business. Xeris Biopharma Holdings Inc operates as a pharmaceutical company with subsidiaries including Xeris Pharmaceuticals, Inc and Strongbridge Biopharma Limited, generating revenue through the development and manufacturing of products such as Recorlev and levoketoconazole.

Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
AQR Capital Management, LLC
largest disclosed fund holder
Profitability→
4,0 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning XERS.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to XERS.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Xeris Biopharma Holdings Inc operates as a pharmaceutical company with subsidiaries including Xeris Pharmaceuticals, Inc and Strongbridge Biopharma Limited, generating revenue through the development and manufacturing of products such as Recorlev and levoketoconazole.

    Classification85 %
    SectorHealth Care
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a highly leveraged capital structure with a debt-to-equity ratio of 16.1, indicating significant reliance on debt financing relative to equity. Total liabilities stand at $369.8 million against total equity of $13.7 million, while long-term debt amounts to $220.3 million. Liquidity is assessed as medium risk, with cash and equivalents of $111.0 million offsetting the high debt load, resulting in a negative net cash position after subtracting total debt.

    Profitability metrics are weak, with a return on equity of 4.05% and a return on assets of 0.14%. Net income is minimal at $0.55 million despite revenue of $291.8 million, suggesting thin margins. Operating income is $24.9 million, and operating cash flow is $28.6 million, providing some cash generation but insufficient to significantly reduce the debt burden or boost returns to industry-standard levels.

    Revenue concentration is not explicitly detailed in segment or geographic breakdowns, but the company’s operations are tied to specific products like Recorlev and levoketoconazole. Manufacturing dependencies are notable, with Lonza Tampa, LLC and Regis Technologies, Inc. identified as key suppliers for development and manufacturing, indicating potential supply chain concentration risks.

    Growth trajectory cannot be assessed due to the absence of historical period data. The current financial snapshot provides a single-period view, limiting trend analysis. Revenue of $291.8 million and net income of $0.55 million represent the latest normalized period, but without multi-year data, long-term growth patterns remain unclear.

    Risk factors include medium liquidity risk and low dilution risk. The key flag of negative net cash after debt subtraction highlights financial stress. Dilution risk is low, with basic and diluted shares outstanding identical at 166.2 million, suggesting no immediate share issuance pressure. However, the high debt load and low equity base pose ongoing solvency concerns.

    Recent events include reconciler enqueue actions for analysis jobs, indicating administrative processing rather than operational developments. No significant news, filing, or transcript observations are present to suggest recent strategic shifts or market-moving events. The company’s subsidiary structure remains stable, with no reported changes in ownership or operational scope.

    Key takeaways
    • High debt-to-equity ratio of 16.1 signals significant financial leverage and potential solvency risk.
    • Minimal net income of $0.55 million on $291.8 million revenue indicates poor profitability.
    • Medium liquidity risk due to negative net cash position after debt subtraction.
    • Low dilution risk with no difference between basic and diluted shares outstanding.
    • Supply chain concentration with key suppliers Lonza and Regis poses operational risk.
    • Lack of historical data prevents assessment of growth trajectory or trend stability.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $8,13
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $13.7M
    Net cashⓘ
    -$109.3M
    Current ratioⓘ
    —
    Debt / equityⓘ
    16.1
    ROAⓘ
    0.1%
    ROEⓘ
    4.0%
    Cash conversionⓘ
    5167.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships7 disclosed relationships · 2 types · extracted from filings & disclosures
    Suppliers2
    LONZA GROUP AGLON.NLBSupplier95%Source ↗
    Regis CorpRGS.OSupplier95%Source ↗
    Subsidiaries5
    EX21:3a2d2fc02be6EX21:3a2d2fc02be6Subsidiarie97%
    EX21:4bd52d1435fcEX21:4bd52d1435fcSubsidiarie97%
    EX21:7c9164660192EX21:7c9164660192Subsidiarie97%
    EX21:970a05af8e8bEX21:970a05af8e8bSubsidiarie97%
    EX21:c353a70a750aEX21:c353a70a750aSubsidiarie97%

    Supply chain

    Vendors → XERS ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSXERSXERSXers.O7 entitiesLONZA GROUP AGPharmaceuticalsRegis CorpDiversified Personal SerUS
    2 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution7 analysts
    Strong buy3
    Buy3
    Hold1
    Sell0
    Strong sell0
    12-month price target$11,29 · Median $10,00
    Low $8,00High $18,00
    Operating income · consensus45,6M USD
    EPS surprise
    −100,0 %
    reported vs consensus · miss
    Revenue surprise
    −24,2 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$8,00
    Mean$11,29
    Median$10,00
    High$18,00
    Spot$8,13
    +38.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin8,5 %Above median
    Net Margin0,2 %Below median
    ROE4,0 %Above median
    D/E16,10Bottom quartile
    Cash Conv51,67Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 1 449 155 sh7 exercises · 12 grants12 insiders
    • KREHER NERISSADirector · Stock Option (Right to Buy) → Common StockAcquired 37 910 @ $8,00grant · 2026-07-01
    • Brady James AloysiusDirector · Stock Option (Right to Buy) → Common StockAcquired 32 996 @ $6,15grant · 2026-06-04
    • Kong GarhengDirector · Stock Option (Right to Buy) → Common StockAcquired 32 996 @ $6,15grant · 2026-06-04
    • JOHNSON JOHNDirector · Stock Option (Right to Buy) → Common StockAcquired 32 996 @ $6,15grant · 2026-06-04
    • HALKUFF DAWNDirector · Stock Option (Right to Buy) → Common StockAcquired 32 996 @ $6,15grant · 2026-06-04
    • PERSKY MARLADirector · Stock Option (Right to Buy) → Common StockAcquired 32 996 @ $6,15grant · 2026-06-04
    • BORMANN-KENNEDY BARBARA-JEAN ANNEDirector · Stock Option (Right to Buy) → Common StockAcquired 32 996 @ $6,15grant · 2026-06-04
    • McCulloch KevinSee Remarks · Stock Option (Right to Buy) → Common StockDisposed 4 @ $3,94exercise · 2026-03-12
    • McCulloch KevinSee Remarks · Stock Option (Right to Buy) → Common StockDisposed 48 894 @ $4,09exercise · 2026-03-12
    • Pieper StevenSee Remarks · Stock Option (Right to Buy) → Common StockDisposed 27 891 @ $4,09exercise · 2026-03-05
    • Pieper StevenSee Remarks · Stock Option (Right to Buy) → Common StockDisposed 14 036 @ $5,93exercise · 2026-03-05
    • Nguyen Anh TuSee Remarks · Stock Option (Right to Buy) → Common StockAcquired 162 162 @ $7,36grant · 2026-01-30
    • Hecht BethSee Remarks · Stock Option (Right to Buy) → Common StockAcquired 162 162 @ $7,36grant · 2026-01-30
    • Shannon John Patrick JrDirector, See Remarks · Stock Option (Right to Buy) → Common StockAcquired 639 639 @ $7,36grant · 2026-01-30
    • McCulloch KevinSee Remarks · Stock Option (Right to Buy) → Common StockAcquired 225 225 @ $7,36grant · 2026-01-30
    • Pieper StevenSee Remarks · Stock Option (Right to Buy) → Common StockAcquired 207 207 @ $7,36grant · 2026-01-30
    • Shannon John Patrick JrDirector, See Remarks · Stock Option (Right to Buy) → Common StockDisposed 64 265 @ $1,55exercise · 2026-01-05
    • Shannon John Patrick JrDirector, See Remarks · Stock Option (Right to Buy) → Common StockDisposed 25 136 @ $1,55exercise · 2026-01-05
    • Shannon John Patrick JrDirector, See Remarks · Stock Option (Right to Buy) → Common StockDisposed 2 900 @ $3,94exercise · 2026-01-05

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Return On Equity
      net_income / total_equity
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Return On Assets
      net_income / total_assets
    Source documents
    • XERIS BIOPHARMA HOLDINGS, INC. Market data — financials · 2026-08-02
    • reconciler_enqueue (reconciler) on XERS.O · 2026-08-02
    • XERS.O HA canonical relationships · 2026-08-02

    Ownership & reference

    Top holders

    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$8M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$13M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$6M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$10M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$25M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$88M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$9M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$8M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$8M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$27M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$15M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$2M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$1M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$23M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$2M
    • Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,00 %$1M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$1M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$1M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$3M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Paul Raymond EdickChairman of the Board, Chief Executive Officer

    Insider activity

    Net selling0 buys · 21 sellsnet -$3,9M12 insiders · last 365d
    • Pieper StevenSee Remarks · Common StockSold 27 600 @ $8,52$235K · 2026-07-07
    • Pieper StevenSee Remarks · Common StockSold 17 400 @ $8,50$148K · 2026-07-06
    • Hecht BethSee Remarks · Common StockSold 16 666 @ $8,03$134K · 2026-07-01
    • McCulloch KevinSee Remarks · Common StockSold 90 000 @ $8,03$723K · 2026-07-01
    • KREHER NERISSADirector · Common StockOther 33 582 · 2026-07-01
    • BORMANN-KENNEDY BARBARA-JEAN ANNEDirector · Common StockSold 16 000 @ $6,09$98K · 2026-06-04
    • BORMANN-KENNEDY BARBARA-JEAN ANNEDirector · Common StockOther 24 193 · 2026-06-04
    • JOHNSON JOHNDirector · Common StockSold 15 000 @ $6,09$91K · 2026-06-04
    • JOHNSON JOHNDirector · Common StockOther 24 193 · 2026-06-04
    • Brady James AloysiusDirector · Common StockOther 24 193 · 2026-06-04
    • Kong GarhengDirector · Common StockOther 24 193 · 2026-06-04
    • PERSKY MARLADirector · Common StockOther 24 193 · 2026-06-04
    • HALKUFF DAWNDirector · Common StockSold 20 000 @ $6,09$122K · 2026-06-04
    • HALKUFF DAWNDirector · Common StockOther 24 193 · 2026-06-04
    • PERSKY MARLADirector · Common StockSold 15 500 @ $5,90$91K · 2026-06-03
    • Hecht BethSee Remarks · Common StockSold 16 667 @ $6,06$101K · 2026-06-01
    • Hecht BethSee Remarks · Common StockSold 16 667 @ $6,23$104K · 2026-05-01
    • Hecht BethSee Remarks · Common StockSold 16 667 @ $5,99$100K · 2026-04-01
    • Brady James AloysiusDirector · Common StockSold 10 834 @ $5,54$60K · 2026-03-30
    • McCulloch KevinSee Remarks · Common StockOther 48 894 @ $4,09$200K · 2026-03-12
    • McCulloch KevinSee Remarks · Common StockOther 4 @ $3,94$16 · 2026-03-12
    • Pieper StevenSee Remarks · Common StockOther 14 036 @ $5,93$83K · 2026-03-05
    • Pieper StevenSee Remarks · Common StockOther 27 891 @ $4,09$114K · 2026-03-05
    • Hecht BethSee Remarks · Common StockSold 100 @ $7,06$706 · 2026-03-02
    • Hecht BethSee Remarks · Common StockSold 16 567 @ $6,24$103K · 2026-03-02

    Short positioning

    10.1Mshares short-21.0% vs prior
    4.38days to cover
    49.4%short of daily vol
    50.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    XERS.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    XERSLON.NLBRGS.OEX21:3a2EX21:4bdEX21:7c9EX21:970EX21:c35Pharmaceutical
    This companySectorSuppliersSubsidiaries

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-07INSIDERPieper Steven sold 27.6k sh — See Remarks ~$235k
    2026-07-06INSIDERPieper Steven sold 17.4k sh — See Remarks ~$148k
    2026-07-01INSIDERHecht Beth sold 16.7k sh — See Remarks ~$134k
    2026-07-01INSIDERMcCulloch Kevin sold 90.0k sh — See Remarks ~$723k
    2026-07-01INSIDERKREHER NERISSA transacted 33.6k sh — Director
    2026-07-01INSIDERKREHER NERISSA acquired 37.9k sh Stock Option (Right to Buy) — Director
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-11FILING8-K filing →
    2026-06-05FILING8-K filing →
    2026-06-04 00:00 UTCINSIDER17 insider transactions — 2026-06 · net sell $503k 6 derivative
    2026-06-04 00:00 UTCINSIDER17 insider transactions — 2026-06 · net sell $503k 6 derivative
    2026-06-04INSIDERBORMANN-KENNEDY BARBARA-JEAN ANNE sold 16.0k sh — Director ~$98k
    2026-06-04INSIDERBORMANN-KENNEDY BARBARA-JEAN ANNE transacted 24.2k sh — Director
    2026-06-04INSIDERJOHNSON JOHN sold 15.0k sh — Director ~$91k
    2026-06-04INSIDERJOHNSON JOHN transacted 24.2k sh — Director
    2026-06-04INSIDERBrady James Aloysius transacted 24.2k sh — Director
    2026-06-04INSIDERKong Garheng transacted 24.2k sh — Director
    2026-06-04INSIDERPERSKY MARLA transacted 24.2k sh — Director
    2026-06-04INSIDERHALKUFF DAWN sold 20.0k sh — Director ~$122k
    2026-06-04INSIDERHALKUFF DAWN transacted 24.2k sh — Director
    2026-06-04INSIDERKong Garheng acquired 33.0k sh Stock Option (Right to Buy) — Director
    2026-06-04INSIDERPERSKY MARLA acquired 33.0k sh Stock Option (Right to Buy) — Director
    2026-06-04INSIDERJOHNSON JOHN acquired 33.0k sh Stock Option (Right to Buy) — Director
    2026-06-04INSIDERHALKUFF DAWN acquired 33.0k sh Stock Option (Right to Buy) — Director
    2026-06-04INSIDERBORMANN-KENNEDY BARBARA-JEAN ANNE acquired 33.0k sh Stock Option (Right to Buy) — Director
    2026-06-04INSIDERBrady James Aloysius acquired 33.0k sh Stock Option (Right to Buy) — Director
    2026-06-03INSIDERPERSKY MARLA sold 15.5k sh — Director ~$91k
    2026-06-01INSIDERHecht Beth sold 16.7k sh — See Remarks ~$101k
    2026-05-07FILING10-Q filing →
    2026-05-07FILING8-K filing →
    2026-05-01 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $104k
    2026-05-01 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $104k
    2026-05-01INSIDERHecht Beth sold 16.7k sh — See Remarks ~$104k
    2026-04-23FILINGDEF 14A filing →
    2026-04-21FILING8-K filing →
    2026-04-01 00:00 UTCINSIDER1 insider transaction — 2026-04
    2026-04-01 00:00 UTCINSIDER1 insider transaction — 2026-04
    2026-04-01INSIDERHecht Beth sold 16.7k sh — See Remarks ~$100k
    2026-03-30 00:00 UTCINSIDER11 insider transactions — 2026-03 · net buy $233k 4 derivative
    Showing the 40 most recent of 62 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage